The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat

Ryan M. Fryer; Akalushi Muthukumarana; Paul C. Harrison; Suzanne Nodop Mazurek; Rong Rhonda Chen; Kyle E. Harrington; Roger M. Dinallo; Joshua C. Horan; Lori Patnaude; Louise K. Modis; Glenn A. Reinhart

doi:10.1371/journal.pone.0052985

Loading metrics

Open Access

Peer-reviewed

Research Article

The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P₁) and Hypertension (S1P₃) in Rat

Ryan M. Fryer ,

* E-mail: ryan.fryer@boehringer-ingelheim.com

Affiliation Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Akalushi Muthukumarana,

Affiliation Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Paul C. Harrison,

Affiliation Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Suzanne Nodop Mazurek,

Affiliation Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Rong Rhonda Chen,

Affiliation Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Kyle E. Harrington,

Affiliation Department of Drug Discovery Support, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Roger M. Dinallo,

Affiliation Department of Drug Discovery Support, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Joshua C. Horan,

Affiliation Department of Medicinal Chemistry, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Lori Patnaude,

Affiliation Department of Immunology and Inflammation, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Louise K. Modis,

Affiliation Department of Immunology and Inflammation, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯
Glenn A. Reinhart

Affiliation Department of Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States of America
⨯

The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P₁) and Hypertension (S1P₃) in Rat

Ryan M. Fryer,
Akalushi Muthukumarana,
Paul C. Harrison,
Suzanne Nodop Mazurek,
Rong Rhonda Chen,
Kyle E. Harrington,
Roger M. Dinallo,
Joshua C. Horan,
Lori Patnaude,
Louise K. Modis

Published: December 28, 2012
https://doi.org/10.1371/journal.pone.0052985

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Heart rate
Is the Subject Area "Heart rate" applicable to this article?

Thanks for your feedback.
Bradycardia
Is the Subject Area "Bradycardia" applicable to this article?

Thanks for your feedback.
Blood pressure
Is the Subject Area "Blood pressure" applicable to this article?

Thanks for your feedback.
Hypertension
Is the Subject Area "Hypertension" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Phosphorylation
Is the Subject Area "Phosphorylation" applicable to this article?

Thanks for your feedback.
Metabolites
Is the Subject Area "Metabolites" applicable to this article?

Thanks for your feedback.
Oral administration
Is the Subject Area "Oral administration" applicable to this article?

Thanks for your feedback.